EC approves new formulation of pegaspargase

Micrograph showing
acute lymphoblastic leukemia
The European Commission (EC) has granted marketing authorization for a lyophilized formulation of pegaspargase (ONCASPAR). The product is intended for use as a component of antineoplastic combination therapy in acute lymphoblastic leukemia patients of all ages. The EC’s approval authorizes Shire to market lyophilized pegaspargase in the 28 member states of the European Union as well as Iceland, Liechtenstein, and Norway. [Read Article]

Technique may be effective for diagnosing NHL

A.G. Unil Perera, PhD
Photo from Georgia State University
Preclinical research suggests infrared spectroscopy could be used to diagnose non-Hodgkin lymphoma (NHL). Researchers used mid-infrared spectroscopy to analyze blood serum derived from mice and differentiate mice with NHL and subcutaneous melanoma from each other and from healthy control mice. The findings suggest infrared spectroscopy can detect biochemical changes induced by NHL and melanoma and therefore has diagnostic potential as a screening technique for these cancers. [Read Article]

Combo should be standard in MM, doc says

Maria-Victoria Mateos, MD, PhD
Study results “strongly support” a new standard of care for transplant-ineligible patients with newly diagnosed multiple myeloma (MM), according to a speaker at the 2017 ASH Annual Meeting. The study, ALCYONE, suggests treatment with bortezomib, melphalan, and prednisone (VMP) can be improved by the addition of daratumumab (D). D-VMP produced deeper responses and prolonged progression-free survival (PFS) when compared to VMP. “In this first phase 3, randomized study with a monoclonal antibody in newly diagnosed multiple myeloma, daratumumab reduced the risk of progression or death by 50%,” said Maria-Victoria Mateos, MD, PhD, of University Hospital of Salamanca in Spain. [Read Article]